Journal: Cell Communication and Signaling : CCS
Article Title: GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2
doi: 10.1186/s12964-025-02356-z
Figure Lengend Snippet: GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
Article Snippet: Cisplatin (Cat. No. HY-17394), SB431542 (TGF-β receptor kinase inhibitors, TRKI, HY-10431), and recombinant human TGFβ1 protein from HEK293 (Cat. No. HY- P70543 ) were purchased from MedChemExpress (MCE).
Techniques: Quantitative RT-PCR, Marker, Expressing, Transfection, Western Blot, Immunofluorescence, Staining, Incubation, Enzyme-linked Immunosorbent Assay